Bausch + Lomb Corporation (BLCO)
16.36
-0.05 (-0.30%)
At close: Feb 18, 2025, 3:59 PM
16.35
-0.05%
After-hours: Feb 18, 2025, 04:10 PM EST
undefined% (undefined)
| Bid | 16 |
| Market Cap | 5.76B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.04 |
| PE Ratio (ttm) | -15.73 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 16.88 |
| Volume | 400,155 |
| Avg. Volume (20D) | 549,922 |
| Open | 16.35 |
| Previous Close | 16.41 |
| Day's Range | 16.25 - 16.48 |
| 52-Week Range | 13.16 - 21.69 |
| Beta | undefined |
About BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date May 6, 2022
Employees 13,000
Stock Exchange NYSE
Ticker Symbol BLCO
Website https://www.bausch.com
Analyst Forecast
According to 12 analyst ratings, the average rating for BLCO stock is "Hold." The 12-month stock price forecast is $19, which is an increase of 16.15% from the latest price.
Buy 41.67%
Hold 50.00%
Sell 8.33%
Next Earnings Release
Bausch + Lomb Corporation is scheduled to release its earnings on Feb 19, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-9.52%
Bausch + Lomb shares are trading lower after the c...
Unlock content with
Pro Subscription
2 months ago
-12.06%
Bausch + Lomb shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and lowered its price target from $24 to $22.
